Moderna D
D
MRNA
223.685
USD
-7.54
(-3.26%)
Market Open
Last updated: · Delayed 15 min
If you had invested in Moderna ago, it would be worth $12,860 today, against $2,708 in SPY and $3,564 in QQQ.
Moderna key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Speculative (losing money)
- Day range
- 221.880 – 231.290
- 52-week range
- 22.280 – 280.800
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 90.51B USD
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- -7.07
- Volume
- 79,045
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.90
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 55.8/100Environment 50 · Social 64 · Governance 53
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 5K
- Website
- modernatx.com
- IPO date
- 7 Dec 2018
Moderna earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
-2.09 USD
Revenue estimate
539.30M USD
Last quarter · Q3 FY2026
EPS0.38Beat +134.5%Revenue1.31BBeat +47.5%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | -1.66 | — | — | — | 302.19M | — | — | -22.32% | |
| Q4 FY2026 | -2.09 | — | — | — | 539.30M | — | — | -20.46% | |
| Q3 FY2026 | -1.10 | 0.38 | +134.55% | — | 890.25M | 1.31B | +47.49% | +29.23% | |
| Q2 FY2026 | -2.03 | -1.97 | +2.96% | — | 102.93M | 145.00M | +40.87% | +2.11% | |
| Q1 FY2026 | -4.45 | -3.40 | +23.60% | — | 236.36M | 389.00M | +64.58% | +263.55% | |
| Q4 FY2025 | -2.54 | -2.11 | +16.93% | — | 635.15M | 678.00M | +6.75% | -29.08% | |
| Q3 FY2025 | -1.87 | -0.51 | +72.73% | -1,800.00% | 920.86M | 1.02B | +10.33% | -45.23% | |
| Q2 FY2025 | -2.99 | -2.13 | +28.76% | — | 893.29M | 142.00M | -84.10% | -41.08% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | -2.28 | — | — | — | 3.68B | — | — | +40.16% |
| FY2027 | -4.34 | — | — | — | 2.63B | — | — | +15.52% |
| FY2026 | -7.71 | — | — | — | 2.27B | — | — | +17.04% |
| FY2025 | -7.84 | -7.27 | +7.24% | — | 1.91B | 1.94B | +1.83% | -39.64% |
| FY2024 | -9.05 | -8.87 | +1.99% | — | 3.21B | 3.22B | +0.33% | -52.84% |
| FY2023 | -13.46 | -12.41 | +7.78% | -162.17% | 6.47B | 6.83B | +5.58% | -63.71% |
| FY2022 | 21.26 | 19.96 | -6.10% | -29.45% | 19.13B | 18.81B | -1.67% | +6.06% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Moderna analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
140.20 USD
-37.32%
Analysts' 1-year price targets range from 25.00 to 305.00, with an average of 140.20.
Past year
1-year forecast
Strong sellStrong buy
Hold
16 ratings
| Buy | 2 | |
| Hold | 9 | |
| Sell | 5 |
12-month price target
| Highest target | 305.00 |
| Average target | 140.20 |
| Lowest target | 25.00 |
| Current price | 223.69 |
Moderna valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Forward P/E (FY2029)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 241.67
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 35.84
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 13.24
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
90.51B USD
+
Total debt
4.18B USD
−
Cash and short-term investments
5.17B USD
=
Enterprise value
89.52B USD
Valuation over time
P/EForward P/E
Moderna against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Revolution Medicines, United Therapeutics, Incyte, and Insmed, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginAt its median55.3%31.5%85.2%Against its peers: 7 of 7Peers' median 86.6%
- Operating marginLowest in 5 years-158.1%-158.1%75.0%Against its peers: 5 of 7Peers' median 25.5%
- Net marginLowest in 5 years-145.2%-145.2%68.8%Against its peers: 5 of 7Peers' median 28.2%
- Return on equityAt its median-32.6%-34.0%86.3%Against its peers: 6 of 7Peers' median 16.6%
- Free cash flow marginBelow its median-106.2%-126.8%75.2%Against its peers: 5 of 7Peers' median 26.4%
- Revenue growthAt its median-39.2%-63.7%2,107.6%Against its peers: 6 of 7Peers' median 10.1%
- Current ratioAt its median3.291.763.67Against its peers: 6 of 7Peers' median 3.98
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Moderna growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 2.53B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- -2.79B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 28.00%
- Operating margin
- -116.04%
- Net margin
- -110.46%
Revenue / Net income
Revenue Net income Net margin
Moderna revenue breakdown
By product
FY2025
93.1%COVID4.1%Stand-ready manufacturing revenue1.1%Grant revenue
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| COVID | 1.81B | 93.1% | — |
| Stand-ready manufacturing revenue | 80.00M | 4.1% | — |
| Grant revenue | 22.00M | 1.1% | -40.5% |
| Collaboration revenue | 13.00M | 0.7% | +8.3% |
| Licensing and royalty revenue | 11.00M | 0.6% | — |
| RSV | 8.00M | 0.4% | — |
By region
FY2025
64.6%United States32.5%Rest Of The World2.9%Europe
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 1.20B | 64.6% | -32.8% |
| Rest Of The World | 603.00M | 32.5% | -25.6% |
| Europe | 53.00M | 2.9% | -91.1% |
Moderna financial health
- Cash and short-term investments
- 5.17B USD
- Total debt
- 4.18B USD
- Net cash
- 992.00M USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- -1.97B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 3.62
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.61
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 3 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 9.45
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Moderna ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 82.26%
- Institutional holders
- 870 (+65)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 93.26%
Who owns the shares
Institutions 82.3% Others 17.7%
As of 30 Jun 2026
Shares free to trade
Free float 377.37M shares ·93.3% Closely held 27.26M shares ·6.7%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 3 | 154.36K | 233.43K |
| Q3 2026 | 0 | 10 | 1.10M | 1.49M |
| Q2 2026 | 0 | 5 | 293.96K | 361.01K |
| Q1 2026 | 0 | 2 | 977.85K | 485.70K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Strategic Pips
7 months ago
Strategic Pips
1 year ago
Strategic Pips
2 years ago
Strategic Pips
2 years ago
More
Title: Moderna
Sector: Healthcare
Industry: Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.